NCT02336698 is a Phase 3 clinical trial of Fulranumab 1 mg in Osteoarthritis, sponsored by Janssen Research & Development, LLC.

Who is sponsoring NCT02336698?

NCT02336698 is sponsored by Janssen Research & Development, LLC.

What drugs are being tested in NCT02336698?

Interventions in NCT02336698: Placebo, Fulranumab 1 mg, Fulranumab 3 mg.

What condition does NCT02336698 study?

NCT02336698 studies Osteoarthritis, Pain.

Is NCT02336698 still recruiting?

NCT02336698 is currently completed. Last updated 2 October 2017.

Last reviewed 2017-10-02 · How we verify

NCT02336698

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002

Completed Phase 3 Last updated 2 October 2017

What this trial tests

Phase 3 trial testing Placebo in Osteoarthritis in 18 participants. Completed in 15 September 2016.

Timeline

13 July 2015

Primary endpoint
15 September 2016

15 September 2016

Quick facts

Lead sponsor	Janssen Research & Development, LLC
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	18
Start date	13 July 2015
Primary completion	15 September 2016
Estimated completion	15 September 2016
Sites	32 locations across Spain, United Kingdom, United States, Poland

Drugs / interventions tested

Placebo
Fulranumab 1 mg — full drug profile →
Fulranumab 3 mg — full drug profile →

Conditions studied

Osteoarthritis — all drugs for Osteoarthritis →
Pain — all drugs for Pain →

Sponsor

Janssen Research & Development, LLC — full company profile →

Who can join

Adults 18 to 99, any sex, with Osteoarthritis or Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not adequately controlled by current pain therapy.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Disease-modifying therapeutic strategies in osteoarthritis: current status and future directions.
Cho Y, Jeong S, Kim H, Kang D, et al · · 2021 · cited 209× · PMID 34848838 · DOI 10.1038/s12276-021-00710-y
Antibodies to watch in 2016.
Reichert JM. · · 2016 · cited 135× · PMID 26651519 · DOI 10.1080/19420862.2015.1125583
An update on targets for treating osteoarthritis pain: NGF and TRPV1.
Obeidat AM, Donner A, Miller RE. · · 2020 · cited 14× · PMID 34178580 · DOI 10.1007/s40674-020-00146-x
Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies.
Kelly KM, Sanga P, Zaki N, Wang S, et al · · 2019 · cited 14× · PMID 31387410 · DOI 10.1080/03007995.2019.1653068
Pharmaceutical therapeutics for articular regeneration and restoration: state-of-the-art technology for screening small molecular drugs.
Chen Y, Sun H, Yao X, Yu Y, et al · · 2021 · cited 9× · PMID 34783870 · DOI 10.1007/s00018-021-03983-8
Antibody and aptamer-based therapies for osteoarthritis: Application of antibodies and promise of aptamers.
Chen H, Ye Z, Korpershoek JV, Creemers LB, et al · · 2025 · cited 2× · PMID 40487355 · DOI 10.1016/j.omtn.2025.102552

Verify or expand the search:

Other trials of Fulranumab 1 mg

Trials testing the same drug.

NCT02289716 — Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 · Phase 3 · completed
NCT02336685 — Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 · Phase 3 · completed
NCT02301234 — Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 · Phase 3 · completed

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

NCT07404891 — Clinical Trial on the Efficacy and Safety of ALT001 in Osteoarthritis · NA · recruiting
NCT07118501 — A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System · recruiting
NCT06631638 — EMPHASYS Cup Positioning in THA With Non-Invasive Navigation (Velys Hip Navigation (VHN)) · NA · recruiting
NCT07198750 — "Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis" · NA · recruiting
NCT07006714 — Preoperative Correction of Vitamin D Deficiency in Total Joint Arthroplasty (TJA) · Phase 4 · active not recruiting

Other Janssen Research & Development, LLC trials

Trials by the same sponsor.

NCT07518186 — A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · Phase 3 · not yet recruiting
NCT07309445 — A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC · recruiting
NCT07499232 — A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease · Phase 3 · not yet recruiting
NCT07438496 — A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus · Phase 3 · recruiting
NCT07227025 — A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02336698 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Research & Development, LLC
Last refreshed: 2 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02336698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing